Shares of Abcam plc (NASDAQ:ABCM – Get Rating) saw an uptick in trading volume on Monday . 590,563 shares were traded  during trading, a decline of 11% from the previous session’s volume of 664,696 shares. The stock last traded at $15.64 and had previously closed at $15.60.

The firm’s 50-day simple moving average is $14.14 and its 200 day simple moving average is $15.15.

Several institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its holdings in shares of  Abcam by 48.7% in the 1st quarter. JPMorgan Chase & Co. now owns 3,044 shares of the company’s stock valued at $56,000 after buying an additional 997 shares during the period.  Bank of New York Mellon Corp grew its holdings in shares of  Abcam by 14.3% in the 1st quarter. Bank of New York Mellon Corp now owns 612,878 shares of the company’s stock valued at $11,209,000 after buying an additional 76,494 shares during the period.  Bank of Montreal Can grew its holdings in shares of  Abcam by 4.6% in the 1st quarter. Bank of Montreal Can now owns 110,763 shares of the company’s stock valued at $2,055,000 after buying an additional 4,835 shares during the period.  BlackRock Inc. grew its holdings in shares of  Abcam by 26.9% in the 1st quarter. BlackRock Inc. now owns 1,473,409 shares of the company’s stock valued at $26,948,000 after buying an additional 311,896 shares during the period.  Finally, Sei Investments Co. grew its holdings in shares of  Abcam by 3.5% in the 1st quarter. Sei Investments Co. now owns 84,427 shares of the company’s stock valued at $1,543,000 after buying an additional 2,864 shares during the period. Institutional investors own  13.91% of the company’s stock.

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.